Skip to main content
    R

    Replimune Group Inc (REPL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.41
    -0.48 (-2.19%)

    Market Cap: $2.08B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Replimune Group Inc (REPL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Replimune Group are Nurix Therapeutics (NRIX), Xencor (XNCR) and Beam Therapeutics (BEAM). By market cap, Replimune Group ranks 6th of the 13 companies on this page; Vericel Corp Ord (VCEL) is the largest at $2.91B. The median P/E of the 3 companies with a P/E is 89.8x.

    Peer Comparison

    REPL's ROIC of -65.4% is below the peer median of -10.3%, and its revenue growth of 0.0% is below the median of 13.3%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Replimune Group (REPL)$2.08BN/AN/A0.0%-65.4%0.0%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Xencor Inc (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Recursion Pharmaceuticals Inc (RXRX)$1.99BN/A23.1x0.0%-51.8%258.5%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Precigen Inc (PGEN)$1.63B98.6x9.9x15.5%18.9%2438.0%0.00%
    Immunocore Holdings Ltd (IMCR)$1.55BN/A2.8x-7.5%-0.5%-1.4%0.00%
    Celldex Therapeutics Inc (CLDX)$2.26BN/AN/A0.0%N/A-97.0%0.00%
    Vericel Corp Ord (VCEL)$2.91B89.8x9.1x10.3%N/A26.5%0.00%
    Sellas Life Sciences Group Inc (SLS)$1.60BN/AN/A0.0%N/A-82.5%0.00%
    Peer median$1.85B89.8x9.1x0.0%-10.3%13.3%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Replimune Group, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Xencor Inc (XNCR)
    Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed...
    XNCR competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Recursion Pharmaceuticals Inc (RXRX)
    Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry...
    RXRX competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Precigen Inc (PGEN)
    Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
    PGEN competitors
    Immunocore Holdings Ltd (IMCR)
    Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
    IMCR competitors
    Celldex Therapeutics Inc (CLDX)
    Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment...
    CLDX competitors
    Vericel Corp Ord (VCEL)
    Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures...
    VCEL competitors
    Sellas Life Sciences Group Inc (SLS)
    SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications...
    SLS competitors

    Frequently Asked Questions About REPL

    Who are Replimune Group's main competitors?

    The companies most similar to Replimune Group include Nurix Therapeutics (NRIX), Xencor (XNCR), Beam Therapeutics (BEAM), Recursion Pharmaceuticals (RXRX) and Vir Biotechnology (VIR), listed from the closest match.

    Who is Replimune Group's biggest competitor?

    Vericel Corp Ord (VCEL) is the largest of the similar companies at $2.91B; Nurix Therapeutics (NRIX) is the closest match by business profile, size, sector and industry.

    How does REPL stock compare with its competitors?

    REPL's net margin is 0.0% against a peer median of 0.0%.

    Which of Replimune Group's competitors pays a higher dividend?

    Replimune Group pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Replimune Group bigger than its competitors?

    No. Replimune Group is 6th by market cap among the 13 companies on this page; the largest is Vericel Corp Ord (VCEL) at $2.91B.